Blog

The results of the TOPGEAR trial on gastric and GEJ adenocarcinoma – EORTC

Photo from EORTC/LinkedIn

Oct 2, 2024, 13:22

The results of the TOPGEAR trial on gastric and GEJ adenocarcinoma – EORTC

EORTC (European Organisation for Research and Treatment of Cancer) shared a post on LinkedIn:

”We’re thrilled to announce the results of the TOPGEAR trial on gastric and gastroesophageal junction adenocarcinoma.

The study showed that the addition of preoperative chemoradiotherapy did not improve progression-free survival or overall survival compared to perioperative chemotherapy alone.

This breakthrough will impact clinical practice worldwide.

Learn more here.”

Source: EORTC/LinkedIn

Adenocarcinoma cancer Cancer research chemoradiotherapy chemotherapy clinical practice EORTC European Organisation for Research and Treatment of Cancer OncoDaily Oncology TOPGEAR trial

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage